Crossmark

Low-dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia

Published Online: 2016-12-12

Published Print: 2017-03

Authors

Tsirigotis, P

Liga, M

Gkirkas, K

Stamouli, M

Triantafyllou, E

Marangos, M

Pessach, I

Sarantopoulos, A

Spyridis, N

Spyridonidis, A
License Information

Text and Data Mining valid from 2016-12-12

Version of Record valid from 2016-12-12
More Information

Article History

Received: 5 June 2016

Revised: 9 August 2016

Accepted: 16 August 2016

First Online: 12 December 2016

Competing interests

: The authors declare no conflict of interest.

Document is current